



# Clinical Antiviral Development Landscape as of December 2024

# Approved Antivirals: COVID-19, Influenza, Smallpox/Other Poxviruses\*

Approved S.A. (n=14)		Approved O.N.A. (n=12)	
Ensitrelvir (S-217622)	Molnupiravir	Azvudine	Umifenovir
Nirmatrelvir/rtv	Remdesivir	Leritrelvir (RAY1216)	Simnotrelvir/rtv
Amantadine	Rimantadine	Enisamium (VR17-04)	Triazavirin
Favipiravir	Baloxavir Marboxil	Favipiravir	Mindeudesivir (VV116)
Laninamivir	Oseltamivir	Triazavirin	Umifenovir
Peramivir	Zanamivir	Enisamium (VR17-04)	NIOCH-14
Tecovirimat	Brincidofovir		

Indication		
COVID-19 (12)	Influenza (11)	Smallpox/Other Poxviruses (3)


- **22** distinct antiviral compounds have received regulatory approval for COVID-19, Influenza, or Smallpox/Other Poxviruses
- **4** compounds are approved for COVID-19 and Influenza (favipiravir, triazavirin, umifenovir, and enisamium)
- **3** compounds have regulatory authorization by Animal Rule Development or similar mechanism
  - Tecovirimat is approved for Smallpox in U.S. & EU, and Cowpox and Mpox in EU only
  - Brincidofovir for Smallpox in U.S.
  - NIOCH-14 for Smallpox in Russia

\*As of December 18, 2024; WHO defined Other National Authority (<https://www.who.int/publications/m/item/list-of-transitional-wlas>).

# Antiviral-Indication Expansions: Preclinical & Clinical Compound/Indications (N=36)

Investigational: Antiviral compounds in clinical phase development for a different virus disease indication.

Approved: Antiviral compounds approved for treatment of a different virus disease indication.



- ▶ 6 of these antivirals (favipiravir, remdesivir, molnupiravir, amantadine, oseltamivir, & zanamivir) are approved for treatment of COVID-19 and/or Influenza.
  - ▶ Adefovir is approved for treating Hepatitis B virus disease and cidofovir is approved for treating CMV disease.
  - ▶ Tecovirimat is approved for treating smallpox.
- ▶ Favipiravir and remdesivir have the most indication expansions under evaluation (9 each).

\*As of December 18, 2024; Clinical phase Investigational (Unapproved) and Approved antivirals being explored for expanded indications.

# Disclaimer

The INTREPID Alliance is a not-for-profit consortium of innovative biopharmaceutical companies committed to accelerating antiviral research, aiming to ensure that we have a stronger pipeline and are better prepared for future pandemics.

As part of our efforts, the INTREPID Alliance maintains and publishes a centralized list of promising investigational candidate compounds, with the purpose of knowledge-sharing and to support better pandemic preparedness. These compounds have been selected based on objective, scientific criteria, using publicly available sources, and at arm's length from commercial influence of our member companies. See criteria listed in the report “Antiviral Clinical Development Landscape and Promising Clinical Compounds.” The designation of certain compounds as promising is based upon currently available information, and exclusively upon an assessment against these criteria.

“Promising” is not a promotional claim. Candidate compounds have not been assessed by regulatory authorities to be safe and efficacious for the treatment of disease in humans. Our content is designed to be factual, informative, and non-commercial. It is not designed or intended to advertise or promote any pharmaceutical product or therapy or to advance the commercial interests of any company.